Update shared on06 Aug 2025
Fair value Decreased 9.19%The consensus price target for OPKO Health has been reduced, primarily reflecting lower revenue growth expectations and a higher discount rate, resulting in a new fair value estimate of $3.62.
What's in the News
- Issued 2025 revenue guidance of $640–$660 million.
- Completed repurchase of 39.47 million shares (5.77% of shares outstanding) for $58.4 million under buyback plan.
- Presented first-in-class oral GLP-2 analog for short bowel syndrome in partnership with Entera Bio; addresses $800 million market dominated by injectable therapies.
- Added to Russell 2000 Defensive Index.
- Added to Russell 2000 Value-Defensive Index.
Valuation Changes
Summary of Valuation Changes for OPKO Health
- The Consensus Analyst Price Target has fallen from $3.99 to $3.62.
- The Consensus Revenue Growth forecasts for OPKO Health has significantly fallen from 6.3% per annum to 4.3% per annum.
- The Discount Rate for OPKO Health has risen from 6.40% to 6.78%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.